Skip to main content
NCBI home page
Netherlands Heart Journal logoLink to Netherlands Heart Journal
. 2004 Feb;12(2):48–54.

Inhibition of the tissue factor pathway of coagulation by recombinant nematode anticoagulant protein c2 during elective coronary stent implantation

AHM Moons, NR Bijsterveld, KT Koch, JCM Meijers, JGP Tijssen, T van der Poll, HR Büller, RJG Peters
PMCID: PMC2497067  PMID: 25696294

Abstract

Background

Exposure of tissue factor (TF) to the circulation during coronary stent implantation initiates coagulation activation and may contribute to the risk of thrombotic complications. In this study, we investigated whether inhibition of TF-factor VIIa by recombinant Nematode Anti-coagulant Protein c2 (rNAPc2) is able to suppress haemostatic and inflammatory activity in patients undergoing elective intracoronary stenting.

Methods

In a randomised, double-blind design, 102 patients received either placebo or rNAPc2 (biological half-life >50 hours) at doses of 3.5, 5.0, 7.5 and 10.0 μg/kg as a single subcutaneous administration two to six hours before angioplasty. All patients also received aspirin, clopidogrel and unfractionated heparin (activated clotting time >250 seconds during angioplasty). Serial blood samples were collected before and after the intervention.

Results

At 30 hours after stenting, all rNAPc2 treatment groups but not the placebo group demonstrated a reduction from baseline of prothrombin fragment F1+2 and D-dimer plasma levels (to 23 and 12% below baseline values at the highest dose, respectively), which were significantly lower in three rNAPc2 groups compared with placebo (p≤0.03). TF plasma levels were initially reduced in all rNAPc2 groups and returned to baseline values 18 hours after stent implantation. These three markers all increased to above baseline values in the placebo group. Levels of P-selectin, antithrombin III and interleukin-8 were not or only slightly affected by the intervention or by rNAPc2, whereas a significant 2.8 to 4.1 fold increase of C-reactive protein plasma levels was found in all patient groups after the procedure.

Conclusion

In contrast to the inflammatory response, coagulation activation after elective coronary stent implantation, which is observed in spite of the use of multiple antithrombotic drugs, can be attenuated by inhibition of the TF-factor VIIa complex using rNAPc2. Inhibition of the TF-mediated pathway of coagulation may be an important target to prevent thrombotic complications after coronary stenting.

Keywords: rNAPc2, coronary stent implantation, coagulation, inflammation

Full text

PDF
48

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asada Y., Hara S., Tsuneyoshi A., Hatakeyama K., Kisanuki A., Marutsuka K., Sato Y., Kamikubo Y., Sumiyoshi A. Fibrin-rich and platelet-rich thrombus formation on neointima: recombinant tissue factor pathway inhibitor prevents fibrin formation and neointimal development following repeated balloon injury of rabbit aorta. Thromb Haemost. 1998 Sep;80(3):506–511. [PubMed] [Google Scholar]
  2. Bergum P. W., Cruikshank A., Maki S. L., Kelly C. R., Ruf W., Vlasuk G. P. Role of zymogen and activated factor X as scaffolds for the inhibition of the blood coagulation factor VIIa-tissue factor complex by recombinant nematode anticoagulant protein c2. J Biol Chem. 2001 Jan 3;276(13):10063–10071. doi: 10.1074/jbc.M009116200. [DOI] [PubMed] [Google Scholar]
  3. Bittl J. A. Coronary stent occlusion: thrombus horribilis. J Am Coll Cardiol. 1996 Aug;28(2):368–370. doi: 10.1016/0735-1097(96)00183-0. [DOI] [PubMed] [Google Scholar]
  4. Buffon A., Liuzzo G., Biasucci L. M., Pasqualetti P., Ramazzotti V., Rebuzzi A. G., Crea F., Maseri A. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol. 1999 Nov 1;34(5):1512–1521. doi: 10.1016/s0735-1097(99)00348-4. [DOI] [PubMed] [Google Scholar]
  5. Courtman D. W., Schwartz S. M., Hart C. E. Sequential injury of the rabbit abdominal aorta induces intramural coagulation and luminal narrowing independent of intimal mass: extrinsic pathway inhibition eliminates luminal narrowing. Circ Res. 1998 May 18;82(9):996–1006. doi: 10.1161/01.res.82.9.996. [DOI] [PubMed] [Google Scholar]
  6. Cunningham M. A., Romas P., Hutchinson P., Holdsworth S. R., Tipping P. G. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages. Blood. 1999 Nov 15;94(10):3413–3420. [PubMed] [Google Scholar]
  7. EPISTENT Investigators Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998 Jul 11;352(9122):87–92. doi: 10.1016/s0140-6736(98)06113-3. [DOI] [PubMed] [Google Scholar]
  8. ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000 Dec 16;356(9247):2037–2044. doi: 10.1016/S0140-6736(00)03400-0. [DOI] [PubMed] [Google Scholar]
  9. Gawaz M., Neumann F. J., Ott I., May A., Schömig A. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation. 1996 Aug 1;94(3):279–285. doi: 10.1161/01.cir.94.3.279. [DOI] [PubMed] [Google Scholar]
  10. Giesen P. L., Fyfe B. S., Fallon J. T., Roque M., Mendlowitz M., Rossikhina M., Guha A., Badimon J. J., Nemerson Y., Taubman M. B. Intimal tissue factor activity is released from the arterial wall after injury. Thromb Haemost. 2000 Apr;83(4):622–628. [PubMed] [Google Scholar]
  11. Lee A., Agnelli G., Büller H., Ginsberg J., Heit J., Rote W., Vlasuk G., Costantini L., Julian J., Comp P. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation. 2001 Jul 3;104(1):74–78. doi: 10.1161/hc2601.091386. [DOI] [PubMed] [Google Scholar]
  12. Losordo D. W., Rosenfield K., Pieczek A., Baker K., Harding M., Isner J. M. How does angioplasty work? Serial analysis of human iliac arteries using intravascular ultrasound. Circulation. 1992 Dec;86(6):1845–1858. doi: 10.1161/01.cir.86.6.1845. [DOI] [PubMed] [Google Scholar]
  13. Mak K. H., Belli G., Ellis S. G., Moliterno D. J. Subacute stent thrombosis: evolving issues and current concepts. J Am Coll Cardiol. 1996 Feb;27(2):494–503. doi: 10.1016/0735-1097(95)00466-1. [DOI] [PubMed] [Google Scholar]
  14. Mallat Z., Hugel B., Ohan J., Lesèche G., Freyssinet J. M., Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation. 1999 Jan 26;99(3):348–353. doi: 10.1161/01.cir.99.3.348. [DOI] [PubMed] [Google Scholar]
  15. Marmur J. D., Merlini P. A., Sharma S. K., Khaghan N., Torre S. R., Israel D. H., Ardissino D., Ambrose J. A. Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty. J Am Coll Cardiol. 1994 Nov 15;24(6):1484–1491. doi: 10.1016/0735-1097(94)90144-9. [DOI] [PubMed] [Google Scholar]
  16. Marmur J. D., Thiruvikraman S. V., Fyfe B. S., Guha A., Sharma S. K., Ambrose J. A., Fallon J. T., Nemerson Y., Taubman M. B. Identification of active tissue factor in human coronary atheroma. Circulation. 1996 Sep 15;94(6):1226–1232. doi: 10.1161/01.cir.94.6.1226. [DOI] [PubMed] [Google Scholar]
  17. Mizuno O., Hojo Y., Ikeda U., Katsuki T., Fukazawa H., Kurosaki K., Fujikawa H., Shimada K. Assessment of coagulation and platelet activation in coronary sinus blood induced by transcatheter coronary intervention for narrowing of the left anterior descending coronary artery. Am J Cardiol. 2000 Jan 15;85(2):154–160. doi: 10.1016/s0002-9149(99)00651-7. [DOI] [PubMed] [Google Scholar]
  18. Moons Arno H. M., Peters Ron J. G., Bijsterveld Nick R., Piek Jan J., Prins Martin H., Vlasuk George P., Rote William E., Büller Harry R. Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. J Am Coll Cardiol. 2003 Jun 18;41(12):2147–2153. doi: 10.1016/s0735-1097(03)00478-9. [DOI] [PubMed] [Google Scholar]
  19. Randolph G. J., Luther T., Albrecht S., Magdolen V., Muller W. A. Role of tissue factor in adhesion of mononuclear phagocytes to and trafficking through endothelium in vitro. Blood. 1998 Dec 1;92(11):4167–4177. [PubMed] [Google Scholar]
  20. St Pierre J., Yang L. Y., Tamirisa K., Scherrer D., De Ciechi P., Eisenberg P., Tolunay E., Abendschein D. Tissue factor pathway inhibitor attenuates procoagulant activity and upregulation of tissue factor at the site of balloon-induced arterial injury in pigs. Arterioscler Thromb Vasc Biol. 1999 Sep;19(9):2263–2268. doi: 10.1161/01.atv.19.9.2263. [DOI] [PubMed] [Google Scholar]
  21. Stassens P., Bergum P. W., Gansemans Y., Jespers L., Laroche Y., Huang S., Maki S., Messens J., Lauwereys M., Cappello M. Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2149–2154. doi: 10.1073/pnas.93.5.2149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Suzuki S., Matsuo T., Kobayashi H., Matsuo M., Shimamo C., Koide M., Sakamoto S. Antithrombotic treatment (argatroban vs. heparin) in coronary angioplasty in angina pectoris: effects on inflammatory, hemostatic, and endothelium-derived parameters. Thromb Res. 2000 May 15;98(4):269–279. doi: 10.1016/s0049-3848(99)00237-6. [DOI] [PubMed] [Google Scholar]
  23. de Swart C. A., Nijmeyer B., Andersson L. O., Holmer E., Sixma J. J., Bouma B. N. Elimination of intravenously administered radiolabelled antithrombin III and heparin in humans. Thromb Haemost. 1984 Aug 31;52(1):66–70. [PubMed] [Google Scholar]

Articles from Netherlands Heart Journal are provided here courtesy of Springer

RESOURCES